SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has fueled fears of further downside, with traders debating whether Black Monday anniversary concerns and AI-related debt risks signal a broader market break. Others point to a strong futures rebound and see a possible relief bounce, while doubting it confirms a lasting recovery.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp market pullback and a subsequent surge in futures have sparked debate over whether the rebound reflects dip-buying and short covering or a temporary bull trap. Traders are also pushing back against Black Monday crash fears, while bearish voices point to lingering downside risk and volatility.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry about debt-funded data-center expansion, financing costs, and whether AI spending can deliver adequate returns. Bulls argue Nebius has a stronger balance sheet and long-term compute demand than more leveraged peers, while bears see broader sector risks and further valuation pressure; claims of forced liquidations or deliberate market manipulation remain speculation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff has put SOXL, a 3 leveraged ETF, under pressure, with traders debating whether concerns about AI spending, debt, inflation and Chinese chip competition signal deeper losses or an oversold dip. The community is split between buying for a rebound and warning that continued volatility could bring further downside.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hotter-than-expected inflation readings and renewed Fed tightening concerns have weighed on rate-sensitive small caps, while technical weakness has added to pressure on IWM. Traders are divided between looking for an oversold bounce and expecting further declines if support fails.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Chinas proposed export controls on solar-manufacturing technologies, including HJT, have put Canadian Solars U.S. cell expansion in focus. Traders debate whether the restrictions could complicate technology access or make its Jeffersonville facility more valuable, while broader optimism about short-squeeze potential is countered by concerns over losses, debt, and execution.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

A semiconductor-sector pullback is weighing on CHPY, with traders linking its decline to weakness in chip and AI-related stocks. Many are treating the dip as a chance to accumulate for the funds weekly distributions, while others worry about further price declines and whether the payouts can offset NAV erosion.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the focus, with the final analysis awaiting the 80th overall-survival event; the last publicly reported count was 78, and the company has not confirmed that the trigger has occurred. Traders are split over the prolonged wait: some see extended patient survival as a possible positive signal, while others worry about trial uncertainty and company silence, amid a sharp share-price decline and speculation about options-related pressure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Anticipation around Cleveland-Cliffs Q3 earnings is driving attention, with bullish traders citing elevated steel prices and contract resets as potential support for a return to profitability and debt reduction, while skeptics question whether those tailwinds can overcome the companys debt and execution challenges. Short-squeeze expectations are also circulating, but remain speculative.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced full-year profit outlook, driven by surging jet-fuel costs, are weighing on shares despite strong travel demand and premium revenue. Traders are divided between concerns that fuel and other expenses will keep squeezing margins and the view that resilient bookings and pricing power could support a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio...

Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages

Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eight analysts that are presently covering the firm, MarketBeat reports. One...

Palisade Bio (PALI) Expected to Announce Earnings on Monday

Palisade Bio (NASDAQ:PALI) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-palisade-bio-inc-stock...

These Stocks Could Rip into the Close

As the market barrels into the final hour of trading, momentum is clustering around a powerful trio of themes, AI infrastructure, next-gen materials, and sustainable agriculture. $KBLB, $LOCL, $MRVL, $POET, $PALI, $FFAI

Analysts Offer Predictions for Palisade Bio Q1 Earnings

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to...

Brokers Issue Forecasts for Palisade Bio Q3 Earnings

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.06) per share for th...

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports...

Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy

Wolfe Research upgraded shares of Palisade Bio to a "strong-buy" rating in a report on Wednesday...

This account has been verified as an official PALI representative.

Verified Account

Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD).

Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).

Palisade Bio Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.41
Prev Close	$1.54
Open	$1.55
Dividend Yield	0.00%
50-Day Moving Average	$1.82
Beta	0.88
Avg. Volume	3.76M
PE Ratio	-2.63

52-Week High	$2.86
52-Week Low	$1.32
Market Capitalization	$245.72M
EPS (Annual)	-$0.3014
Price to Book	2.01
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

PALI Fundamentals